39 results about "Involucrin" patented technology

The present invention provides human involucrin (hINV) sequences having tissue specific and cell type specific promoter activity. The sequences provided herein direct expression to suprabasal cells of stratifying epithelia. The invention further provides methods for the production of transgenic animals which contain a hINV promoter sequence which directs the expression of human papillomavirus 16 oncogenes (or other oncogenes). These animals display cervical and epidermal hyperplasias as well as cancer of the trachea, esophagus, colon, epidermis, anus / rectum, lymph nodes, spleen and lung. The animals of the invention provide a useful model for screening potential anti-neoplastic compounds, carcinogens, and co-carcinogens for a number of cancers.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in sepsis patients. In particular, the invention relates to using assays that detect one or more biomarkers selected from the group consisting of Insulin-like growth factor-binding protein 7, Beta-2-glycoprotein 1, Metalloproteinase inhibitor 2, Alpha-1 Antitrypsin, Leukocyte elastase, Serum Amyloid P Component, C-X-C motif chemokine 6, Immunoglobulin A, Immunoglobulin G subclass I, C-C motif chemokine 24, Neutrophil collagenase, Cathepsin D, C-X-C motif chemokine 13, Involucrin, Interleukin-6 receptor subunit beta, Hepatocyte Growth Factor, CXCL-1, -2, -3, Immunoglobulin G subclass II, Metalloproteinase inhibitor 4, C-C motif chemokine 18, Matrilysin, C-X-C motif chemokine 11, and Antileukoproteinase as diagnostic and prognostic biomarker assays of renal injury in the sepsis patient.

The gene clone and expression of Japonese lampreyí»s oral gland model proteins RGD with antineoplastic action are disclosed. Three cDNA sequences with said model proteins RGD and their clones, the protein sequence and its expression in engineered bacteria, and the action of proteins RGD in closing the signal transfer channel to suppress the vascular neogenesis and tumor cell reproduction for antineoplastic purpose are also disclosed.

The invention provides the use of silica for cosmetic and / or medical treatment of skin, including improving and enhancing the skin-barrier, anti-aging treatment and photo-protective treatment. The invention is based on the finding that silica exhibits a multi-faceted biological effect useful in the cosmetic and / or therapeutic treatment of skin for the above purposes. Specifically, it has been shown that silica induces markers (involucrin, filaggrin and transglutaminase-1) for skin barrier formation in keratinocytes, induces collagen expression in dermal fibroblasts and inhibits UVA-induced up-regulation of photo-aging markers (matrix metalloproteinase MMP-1 and cytokine IL-6).

Integrin-linked kinase (ILK) and Akt / protein kinase B (PKB) are important mediators of signaling in cardiomyocytes and can both prevent damage and promote healing associated with ischemic injury to the heart. Thus, the present invention provides for methods of screening for agents that increase the expression of ILK and / or Akt / PKB. Methods of treatment based on such agents are also provided.

Contortrostatin, a homodimeric disintegrin, modulates the adhesion, motility, and invasiveness of integrin expressing tumor cells. When formulated as a pharmaceutically acceptable composition, the proteins can be used to treat patients by inhibiting or disrupting disease processes associated with an integrin binding to an αvβ3 or αvβ5 integrin.

The present invention relates to a composition for external skin application having a skin-moisturizing effect, which comprises gallocatechin gallate as an active ingredient. More particularly, the composition for external skin application comprises gallocatechin gallate as an active ingredient to activate peroxisome proliferator activated receptor isoform alpha (PPAR-α), to stimulate expression of filaggrin and involucrin that are skin-moisturizing factors, and thus to provide excellent anti-drying and skin-moisturizing effects. More particularly, the composition for external skin application may further comprise theobromine and quercetin in addition to gallocatechin gallate to maximize such effects.

Disintegrin variants and pharmaceutical uses thereof are disclosed. The disintegrin variant includes an isolated polypeptide that has integrin αvβ3 receptor-antagonist activity and substantially reduced integrin αllbβ3 and / or α5β1 receptor-blocking activity as compared to a wild-type disintegrin. The variant is encoded by a modified disintegrin nucleotide sequence that encodes a modified amino acid sequence, resulting in a polypeptide having substantially reduced affinity to integrin αllbβ3 and / or α5β1 as compared to a wild-type disintegrin. The variant is useful for treatment and / or prevention of αvβ3 integrin-associated diseases in a mammal, which include osteoporosis, bone tumor or cancer growth, angiogenesis-related tumor growth and metastasis, tumor metastasis in bone, malignancy-induced hypercalcemia, angiogenesis-related eye diseases, Paget's disease, rheumatic arthritis, and osteoarthritis. The angiogenesis-related eye diseases include age-related macular degeneration, diabetic retinopathy, corneal neovascularizing diseases, ischaemia-induced neovascularizing retinopathy, high myopia, and retinopathy of prematurity.

The present invention relates to a class of compounds represented by formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of Formula (I), and methods of selectively antagonizing the ανβ3 and / or the ανβ5 integrin without significantly antagonizing the IIb / IIIa integrin.

The invention discloses an Fc-FF-RGD composite. The Fc-FF-RGD composite is characterized in that the composite is a polypeptide analogue sequence composed of ferrocenecarboxylic acid, biphenyl alanine and arginine-glycine-aspartic acid. Compared with the prior art, the Fc-FF-RGD composite has the following advantages that an RGD ligand on hydrogel can be combined with alpha5beta1 integrin on the surfaces of cells so that adhesion and multiplication of the cells are promoted and a good biological nano material application potential is shown; and furthermore, self-assembled nano small balls can identify the alpha5beta1 integrin on the surfaces of cells, so that the Fc-FF-RGD composite can be used as a drug transportation carrier to realize the aim of enhancing the anti-tumor effect.

The invention discloses cornea mid-term preserving fluid and a preparation method thereof. Based on 1000mL, the mid-term preserving fluid consists of the following ingredients: 4g to 5g of minimum essential medium, 4g to 5g of tissue culture medium 199, 10g to 20g of low-molecular-weight dextranum, 20g to 30g of chondroitin sulfate, 100mg to 150mg of sodium pyruvate, 3g to 4g of HEPES, 20ml to 40ml of calf serum, 10ml to 20ml of non-essential amino acid, 1ml to 2ml of gentamicin sulphate, 100 microliters to 200 microliters of basic fibroblast growth factor and the balance of double distilled water. The cornea mid-term preserving fluid can promote the repair of damaged cells on corneal endothelium and the reconstruction of cellular morphology, can adjust the expression of different integrins on the surface of a cell membrane, can promote the adhesion growth of the cell and can stimulate the proliferation of the endothelial cells, and an effect for reducing the cell apoptosis and maintaining the morphology and activity of the cells can be realized for the mid-term preserved cornea.

The invention provides the use of extracts from algae for cosmetic and / or medical treatment of skin, including improving and enhancing the skin-barrier, anti-aging treatment and photo-protective treatment. The invention is based on the finding that extracts from algae obtainable from saline hot water sources exhibit a multi-faceted biological effect useful in the cosmetic and / or therapeutic treatment of skin for the above purposes. Specifically, it has been shown that such algae extracts induce markers (involucrin, filaggrin and transglutaminase-1) for skin barrier formation in keratinocytes, induce collagen expression in dermal fibroblasts and inhibit UVA-induced up-regulation of photo-aging markers (matrix metalloproteinase MMP-1 and cytokine IL-6).

Proteins comprising the amino acid sequence of human disintegrin and DNA sequences encoding the human disintegrin protein are identified. Also described are methods for determining the activity of the disintegrin and for identifying compounds capable of binding to and inhibiting the disintegrin protein. Recombinant expression vectors comprising the DNA sequences encoding the disintegrin, host cells comprising the recombinant expression vector, and antibodies to the disintegrin protein and screening methods for detecting levels of disintegrin protein are exemplified.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more biomarkers selected from the group consisting of Beta-nerve growth factor, Interleukin-17A, Follitropin subunit beta, Collagenase 3, Follistatin, Vitamin D Binding Protein, Islet amyloid polypeptide, Insulin C-peptide, Complement Factor H, Gastric inhibitory polypeptide, Glucagon-like peptide 1, Glucagon, Involucrin, Type II cytoskeletal Keratin-1 / Keratin-10, Type II cytoskeletal Keratin-6A / 6B / 6C, Osteocalcin, Lipopolysaccharide, Pancreatic prohormone, Peptide YY, Agouti-related protein, Ciliary neurotrophic factor, Appetite-regulating hormone, Transthyretin, Insulin receptor substrate 1, and NF-kappa-B inhibitor alpha as diagnostic and prognostic biomarker assays in renal injuries.

The invention discloses a cancer cell-targeting structural molecule and a use thereof. A molecule shown in the formula (I) reacts with a connection molecule containing a carboxyl structure and a maleimide group so that the cancer cell-targeting structural molecule is produced by a dehydration synthesis reaction of an amino group and a carboxyl group. The cancer cell-targeting structural molecule can be bonded with a sulfydryl (-SH)-modified nucleotide molecule, can be directly applied to a human body by blood vessel administration, can be specifically bonded with cancer cells expressing integrin family alpha v beta 3 acceptors or with new vessel endothelial cells in cancer tissue, can effectively penetrate a cell membrane by receptor-mediated endocytosis, and can convey the nucleotide molecule into cytoplasm. In the formula (I), n is in a range of 1-10.

The invention provides a structure modified RGD polypeptide, a complex formed by the polypeptide and radionuclides and a medicinal composition containing the complex. The medicinal composition is usedfor diagnosing or treating integrin alpha v beta 3 positive tumors. The complex has the following definitions: A in the A-(L)n-RGD polypeptide has a structure as shown in the specification, L represents a linker arm molecule and has a structure as shown in the specification, and m is an integer of 1-8.

The present invention provides for novel compositions and methods for delivering genes of interest to stem cells using vectors that contain differentiation-specific transcriptional regulatory elements. For example, stem cells in the internal epithelia could be transfected with a vaccine construct, which has an epithelial cell differentiation-specific promoter driving the expression of viral envelope proteins. When the promoter used is specific for terminally differentiated epithelial cells, then the viral envelope proteins will be expressed only in the upper part of the epithelia and therefore, stimulate the immune response. The infected epithelial stem cells in the basal layer will continue to produce new antigen-expressing cells, without being eliminated by the immune response. This invention will be useful in the development of vaccines against viral agents that target the internal mucosa like HIV.

The present invention provides compounds and pharmaceutical compositions of a peptidomimetic ligand, e.g. LLP2A, conjugated with a bisphosphonate drug, e.g. Alendronate. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of osteoporosis and for the promotion of bone growth due to their specificity for the α4β1 integrin on mesenchymal stem cells and for the surface of bone.

A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the group consisting of α4β1, α5β1, α4β7, αvβ3 and αLβ2, and contacting the treated cells with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells or agonist compounds to a mammal.

The invention discloses the bone bridge protein. The invention also discloses the application of cytokine, acceptor and inhibiting agent in diagnosing and treating RP. The invention also provides the diagnosis agent case. The research expresses that the expression of OPN on film infiltration T cell has great relation with the local inflammation environment. The over expression of OPN on film infiltration T cell has relation with the high expression of film T cell OPN acceptor selective. The IL-10 in RP patient can stimulate T cell to heighten the OPN expression, and the IL-10 antibody can interdict the action.

Modulation of the integrin-linked kinase (ILK) signaling pathway is used to enhance the remodeling process relevant to a wide range of cardiac diseases. More specifically, a process to instigate beneficial human cardiac hypertrophy or for post myocardial infarction (MI) remodeling comprising illiciting an overexpression of ILK, is described. The ILK signaling pathway is also used as a means for cardiac stem cell proliferation and self-renewal

The invention provides an RGD peptide-epimedium flavone combination synthesized by combining two structural units of RGD peptides and epimedium flavone which have pharmacological activities of different action mechanisms on osseous metabolic diseases, and also provides a synthesis method thereof. The compound of the invention has two receptor combining sites and simultaneously has the capability of combining estrogen receptors of icaritin and the capability of combining integrins alphaVbeta3 of RGD, and the capabilities of combining the two different receptors can produce a synergistic effect to greatly improve the curative activity of the medicament on osteoporosis and osseous metabolic diseases. The synthesis method has the advantages of high yield, high synthesis speed and easy purification of products.

Novel and effective anti-fibrosis agents are obtained. An anti-fibrosis agent containing an antagonist for integrin α8β1 is used. In addition, used is an antagonist containing an anti-integrin α8β1 antibody that specifically binds to at least one amino acid in a cap subdomain of an integrin α8 chain and a periphery thereof. Also, used is an anti-fibrosis agent containing an anti-integrin α8β1 antibody that specifically binds to R120 of an integrin α8 chain and a periphery thereof or S132 and a periphery thereof. Note that the above antagonists may each be an anti-integrin α8β1 antibody capable of binding to any of integrins α8β1 derived from a human, mouse, and rat.

The present invention provides a crude extract from the bark of an Acer rubrum (AR) tree and / or Picea mariana (PM), method of preparation and its use for inhibiting the signs of skin aging (such as wrinkles and / or dehydration) caused by at least one of: increased elastase activity, increased collagenase activity, decreased elastin synthesis, decreased collagen synthesis or decreased involucrin synthesis, in skin fibroblast cells, particularly those of a human subject.

The present invention relates to human laminin α2 chain LG3 domain and active peptides promoting cell adhesion, spreading, migration, and neurite outgrowth. More particularly, it was found that when nerve cells are incubated using human laminin α2 chain LG3 domain and active peptides in the LG3 domain, cell adhesion, spreading, migration, and neurite outgrowth of nerve cells promote and the promotion of cell adhesion, spreading, migration, and neurite outgrowth of nerve cells are integrin-mediated and achieved by the activation of PKCδ and FAK phosphorylation. Thus, the present invention can be very useful for researches on cell adhesion, spreading, migration, and neurite outgrowth activities of cells which are focused on nerve cells and mediated by various extracellular matrix proteins including laminin, manufacture of artificial nerve conduits, burns treatment, wounds treatment, and tissue regeneration.

The gene clone and expression of Japonese lamprey's oral gland model proteins RGD with antineoplastic action are disclosed. Three cDNA sequences with said model proteins RGD and their clones, the protein sequence and its expression in engineered bacteria, and the action of proteins RGD in closing the signal transfer channel to suppress the vascular neogenesis and tumor cell reproduction for antineoplastic purpose are also disclosed.

The invention discloses a fusion protein HFBI-RGD gene and protein. The nucleotide sequence of the fusion protein HFBI-RGD gene is shown as SEQ ID NO.1. The fusion protein HFBI-RGD provided by the invention has the characteristics of good solubility, short production cycle and high yield. The HFBI-RGD fusion protein not only has the structure and function of HFBI, but also has cell adhesion activity, the fusion protein can locate at a tumor site containing integrin and therefore has good targeting properties. The HFBI-RGD fusion protein still can serve as an emulsifier and enable small oil droplets exist in water stably, and can be used as dispersant to disperse graphene, carbon nanotubes and hydrophobic fluorescent probes to solve the dispersion problem of hydrophobic materials, moreover,as the fusion protein contains short peptide RGD, the fusion protein is endowed with integrin targeting properties, and can be used in tumor diagnosis, drug delivery and other fields.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in sepsis patients. In particular, the invention relates to using assays that detect one or more biomarkers selected from the group consisting of Insulin-like growth factor-binding protein 7, Beta-2-glycoprotein 1, Metalloproteinase inhibitor 2, Alpha-1 Antitrypsin, Leukocyte elastase, Serum Amyloid P Component, C-X-C motif chemokine 6, Immunoglobulin A, Immunoglobulin G subclass I, C-C motif chemokine 24, Neutrophil collagenase, Cathepsin D, C-X-C motif chemokine 13, Involucrin, Interleukin-6 receptor subunit beta, Hepatocyte Growth Factor, CXCL-1, -2, -3, Immunoglobulin G subclass II, Metalloproteinase inhibitor 4, C-C motif chemokine 18, Matrilysin, C-X-C motif chemokine 11, and Antileukoproteinase as diagnostic and prognostic biomarker assays of renal injury in the sepsis patient.